22nd Century Group, Inc (NASDAQ:XXII) Short Interest Update

22nd Century Group, Inc (NASDAQ:XXII) saw a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 50,192 shares, an increase of 73.5% from the January 29th total of 28,931 shares. Currently, 9.8% of the shares of the company are short sold. Based on an average daily trading volume, of 45,168 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily trading volume, of 45,168 shares, the days-to-cover ratio is currently 1.1 days. Currently, 9.8% of the shares of the company are short sold.

22nd Century Group Price Performance

XXII opened at $4.57 on Friday. 22nd Century Group has a 1-year low of $4.41 and a 1-year high of $841.80. The stock has a market cap of $2.33 million, a P/E ratio of -0.01 and a beta of 1.07. The stock’s 50 day simple moving average is $9.54 and its 200 day simple moving average is $17.92.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of 22nd Century Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of 22nd Century Group in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On 22nd Century Group

An institutional investor recently raised its position in 22nd Century Group stock. Anson Funds Management LP raised its holdings in shares of 22nd Century Group, Inc (NASDAQ:XXII) by 677.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 763,212 shares of the biotechnology company’s stock after acquiring an additional 665,000 shares during the quarter. Anson Funds Management LP owned approximately 149.65% of 22nd Century Group worth $588,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.06% of the company’s stock.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.